BNET Industries

Centocor Inc.

is in the Pharma Industry

Last Fiscal Year Sales:$1.0B
  • Private
  • US
Dow Jones Description

Injectable Monoclonal Antibody-Based Pharmaceuticals Mfr & Developer for Cardiovascular, Infectious & Autoimmune Diseases

CFO & Vice President
Richard A. Bierly
Number of Employees 3,000
Contact Information

800 Ridgeview Dr

Horsham, Pennsylvania 19044

www.centocor.co...

(610) 651-6000

NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413

Recent Events

  • Litigator of the Week: Dianne Elderkin of Woodcock Washburn

    7/04/09 - Lawsuit Filed - View Story

Decision Makers

Name (plus bio) Position
Richard A. Bierly CFO & Vice President
Daniel Everitt Vice President of Clinical Pharmacology and Global Pharmacovigilance
Ronald E. Schmid Vice President, Corp Communications
William R Tolbert Vice President
David P. Holveck Director

Organization Position Status
Centocor, Inc. CFO & Vice President Current

Organization Position Status
Centocor, Inc. Vice President of Clinical Pharmacology and Global Pharmacovigilance Current
Institute for Oneworld Health Board of Directors Current
SmithKline Beecham Corporation Director of Clinical Pharmacology Former
Neuroscience, Inc Group Director Former

Organization Position Status
Centocor, Inc. Vice President, Corp Communications Current

Organization Position Status
Advanced Tissue Sciences, Inc. Vice President Current
Centocor, Inc. Vice President Current
Invitron Limited Vice President Current
Merchant-Taylor International, Inc Senior Associate Current

David P. Holveck was appointed President, Chief Executive Officer, and a Director of Endo in April 2008. Prior to joining Endo, Mr. Holveck was President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson & Johnson since 2004. Mr. Holveck joined Johnson & Johnson as a company Group Chairman in 1999, following the acquisition of Centocor, Inc., by Johnson & Johnson. Mr. Holveck was Chief Executive Officer of Centocor, Inc., at the time of the acquisition. Mr. Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. Prior to joining Centocor, he held positions at General Electric Company, Corning Glass Works, and Abbott Laboratories. Mr. Holveck is a member of the Board of Trustees for the Fund for West Chester University and the Board of Directors of the Eastern Technology Council as well as the Board of Directors of Light Sciences Oncology, Inc.

Organization Position Status
Endo Pharmaceuticals Holdings Inc. President & Chief Executive Officer Current
Johnson & Johnson Development Corp. Vice President, Corporate Development Current
Tengion, Inc. Current
Biotechnology Industry Organization board member Current
Eastern Technology Council Board Member Current
Centocor, Inc. Director Current
University City Science Center Board of Directors Current
Light Sciences Oncology, Inc. Board of Directors Current
Liberty Science Center, Inc. Board Member Current
Endo Pharmaceuticals Holdings Inc. Board of Directors Current
Centocor, Inc. Chief Executive Officer Former
Johnson & Johnson President, Corporate Development Former
Centocor, Inc. president Former
Centocor, Inc. chief operating officer Former
General Electric Company Team Member Former
Abbott Laboratories Team Member Former
Corning Glass Works Team Member Former
Johnson & Johnson Development Corp. President Former
The Group Inc. Chairman Former
Johnson & Johnson Development Corp. Company Group Chairman Former
Johnson & Johnson Company Group Chairman Former
West Chester University B.S. Degree In Education Former

Executive News

  • Endo Pharmaceuticals Introduces Valstar (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer

    Pharma Live - 9/05/09 - View Story

  • FDA extends review on Endo drug

    Philadelphia Inquirer - 9/03/09 - View Story

  • Endo Pharmaceuticals (ENDP) Says FDA Extends Review Date for Testosterone Treatment 9/3/2009

    BioSpace - 9/03/09 - View Story

  • Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive...

    Reuters - 9/03/09 - View Story

  • Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer

    PR Newswire - 9/03/09 - View Story

  • Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate...

    Reuters - 9/02/09 - View Story

  • Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism

    PR Newswire - 9/02/09 - View Story

  • FDA taking more time to review Endo hypogonadism drug

    Philadelphia Business Journal - 9/02/09 - View Story

  • Endo partners with ProStrakan to market testosterone transdermal gel

    TradingMarkets - 8/27/09 - View Story

  • Endo to commercialize Fortesta in the U.S.

    Drug Store News - 8/26/09 - View Story

  • Endo licenses ProStrakan's testosterone gel Fortesta in US for up to $210 million

    PSL Group - 8/26/09 - View Story

  • Endo buys rights to ProStrakan testosterone replacement gel Fortesta

    Biz Journals - 8/26/09 - View Story

  • Endo In Deal To Sell ProStrakan's Testosterone Gel In US

    Morningstar.com - 8/26/09 - View Story

  • Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.

    PR Newswire via Yahoo! - 8/26/09 - View Story

  • Biotech 2009 to Feature Endo Pharmaceuticals President and CEO, David P. Holveck, as Dinner...

    Forbes.com - 8/18/09 - View Story

  • Endo Pharmaceuticals's COO resigns

    TradingMarkets - 8/13/09 - View Story

  • Endo Pharmaceuticals (ENDP) Announces Resignation of Chief Operating Officer

    BioSpace - 8/12/09 - View Story

  • Endo Pharmaceuticals Announces Resignation of Chief Operating Officer

    Reuters - 8/12/09 - View Story

  • Endo Pharmaceuticals Announces Resignation of Chief Operating Officer

    Yahoo! Canada - 8/12/09 - View Story

advertisement
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement